

Mario Masarone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7444465/publications.pdf>

Version: 2024-02-01

109
papers

2,836
citations

186265
28
h-index

189892
50
g-index

114
all docs

114
docs citations

114
times ranked

4951
citing authors

#	ARTICLE	IF	CITATIONS
1	Associated screening for HCV and SARS-CoV2 infection in an urban area of Southern Italy: A cohort study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 171-173.	2.0	3
2	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.	7.3	12
3	Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno. <i>Liver International</i> , 2022, 42, 1467-1469.	3.9	11
4	Screening for hepatitis C at the time of the pandemic: Need to adjust the shot. <i>Liver International</i> , 2022, 42, 1918-1919.	3.9	2
5	Alcoholic Consumption of Young Italians During the SARS-CoV-2 Pandemic. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 126-135.	0.8	2
6	The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials. <i>Nutrients</i> , 2021, 13, 933.	4.1	50
7	The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. <i>Nutrients</i> , 2021, 13, 1314.	4.1	34
8	Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study. <i>BMJ Open</i> , 2021, 11, e043112.	1.9	0
9	Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives. <i>Nutrients</i> , 2021, 13, 1679.	4.1	14
10	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , 2021, 53, 677-681.	0.9	13
11	Solving the gap between HCV detection and treatment in prison. HCV-RNA testing and treatment in a cohort of new arriving convicts in Southern Italy. <i>Reviews on Recent Clinical Trials</i> , 2021, 16, .	0.8	3
12	Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. <i>Liver International</i> , 2021, 41, 2228-2232.	3.9	13
13	Viral hepatitis: Milestones, unresolved issues, and future goals. <i>World Journal of Gastroenterology</i> , 2021, 27, 4603-4638.	3.3	21
14	Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. <i>Metabolomics</i> , 2021, 17, 12.	3.0	37
15	PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial. <i>Frontiers in Medicine</i> , 2021, 8, 734847.	2.6	10
16	Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System. <i>Frontiers in Medicine</i> , 2021, 8, 781567.	2.6	16
17	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , 2020, 52, 937-941.	0.9	53
18	Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy. <i>Life</i> , 2020, 10, 359.	2.4	7

#	ARTICLE	IF	CITATIONS
19	The Bisphenol A Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3369.	2.6	16
20	Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program. <i>Digestive and Liver Disease</i> , 2020, 52, 541-546.	0.9	21
21	Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 26, 261-268.	0.9	20
22	The diagnostic conundrum in non-alcoholic fatty liver disease. <i>Exploration of Medicine</i> , 2020, 1, .	1.5	6
23	Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells. <i>Oncology Reports</i> , 2019, 41, 1476-1486.	2.6	26
24	Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-12.	4.0	43
25	Real-life efficacy and safety of glecaprevir/pibrentasvir in HCV-infected patients with chronic kidney disease. <i>GastroHep</i> , 2019, 1, 166.	0.6	2
26	Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3134.	2.6	39
27	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3415.	2.6	90
28	HCV point-of-care screening programme and treatment options for people who use drugs in a metropolitan area of Southern Italy. <i>Liver International</i> , 2019, 39, 1845-1851.	3.9	11
29	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. <i>Liver International</i> , 2019, 39, 1852-1859.	3.9	31
30	Preclinical evaluation of Endothelial Dysfunction by peripheral artery tonometry and its correlations with untargeted metabolomic profiles in NAFLD. <i>Digestive and Liver Disease</i> , 2019, 51, e27-e28.	0.9	1
31	HCV-Ab sero-prevalence in persons who inject drugs in a Province of Southern Italy: results of a screening program. <i>Digestive and Liver Disease</i> , 2019, 51, e17.	0.9	0
32	Hepatitis C virus prevalence in a cohort of jailbirds in a city of Southern Italy. <i>Digestive and Liver Disease</i> , 2019, 51, e59.	0.9	0
33	Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: A systematic review and meta-analysis. <i>Liver International</i> , 2019, 39, 1292-1306.	3.9	35
34	Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease. <i>Digestive and Liver Disease</i> , 2019, 51, e66.	0.9	1
35	Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis. <i>Antiviral Therapy</i> , 2018, 23, 129-138.	1.0	33
36	HCV Genotype-3h, a Difficult-to-Diagnose Sub-Genotype in the DAA Era. <i>Antiviral Therapy</i> , 2018, 23, 605-609.	1.0	4

#	ARTICLE	IF	CITATIONS
37	Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 826-837.	3.7	51
38	Virological patterns of HCV patients with failure to interferon-free regimens. <i>Journal of Medical Virology</i> , 2018, 90, 942-950.	5.0	14
39	Pressure support ventilation vs Continuous positive airway pressure for treating of acute cardiogenic pulmonary edema: A pilot study. <i>Respiratory Physiology and Neurobiology</i> , 2018, 255, 7-10.	1.6	11
40	Metabolomics in the progression of non alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2018, 50, 18.	0.9	2
41	Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma. <i>Hepatology</i> , 2018, 67, 48-55.	7.3	76
42	Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate—a pilot study. <i>Internal and Emergency Medicine</i> , 2018, 13, 901-906.	2.0	3
43	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , 2018, 68, 33-41.	3.7	19
44	Multifactor risk evaluation in patients who have eradicated HCV infection: an interim analysis in the PITER cohort. <i>Journal of Hepatology</i> , 2018, 68, S308-S309.	3.7	0
45	Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-12.	4.0	28
46	Metabolomics in the progression of fatty liver disease. <i>Journal of Hepatology</i> , 2018, 68, S568-S569.	3.7	2
47	Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-14.	4.0	447
48	Non alcoholic fatty liver disease and eNOS dysfunction in humans. <i>BMC Gastroenterology</i> , 2017, 17, 35.	2.0	45
49	Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo Studio di Virus e Terapia) (PITET). <i>Journal of Hepatology</i> , 2017, 66, S535-S536.	3.7	1
50	Clinical characterization and economic impact evaluation of anti-HCV DAA treatment failure: real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER). <i>Journal of Hepatology</i> , 2017, 66, S535-S536.	3.7	1
51	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	8.1	15
52	Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis. <i>Nutrients</i> , 2017, 9, 1074.	4.1	18
53	Adiponectin in hepatology. <i>Minerva Biotechnology and Biomolecular Research</i> , 2017, 30, .	0.5	3
54	Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. <i>PLoS ONE</i> , 2017, 12, e0178473.	2.5	79

#	ARTICLE	IF	CITATIONS
55	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	2.5	37
56	A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells. <i>In Vivo</i> , 2017, 31, 609-618.	1.3	13
57	Pharmacotherapy of alcoholic liver disease in clinical practice. <i>International Journal of Clinical Practice</i> , 2016, 70, 119-131.	1.7	24
58	New chitosan-coated liposomes for controlled release of active substances in HepG2 cells: Synthesis, biological characterization, cell viability and anti-inflammatory studies. <i>Digestive and Liver Disease</i> , 2016, 48, e236.	0.9	0
59	Liver biopsy in Type 2 Diabetes Mellitus: Steatohepatitis represents the sole feature of liver damage. <i>Digestive and Liver Disease</i> , 2016, 48, e237.	0.9	0
60	P.01.4 ENDOCAN AS SERUM MARKER OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND/OR TYPE 2 DIABETES. <i>Digestive and Liver Disease</i> , 2016, 48, e131.	0.9	0
61	Impact of SVR and Type 2 Diabetes Mellitus on liver stiffness and liver functionality in HCV infected patients with severe liver disease treated with DAA: A real life study. <i>Digestive and Liver Disease</i> , 2016, 48, e234.	0.9	0
62	Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2016, 113, 179-186.	2.8	7
63	Alcoholic Liver Disease and Hepatitis C Chronic Infection. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 201-207.	0.8	7
64	Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 159-166.	0.8	30
65	HIV Vaccine for Prevention and Cure, A Mission Possible. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 290-296.	0.8	7
66	Epidemiology and Natural History of Alcoholic Liver Disease. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 167-174.	0.8	52
67	Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 306-316.	0.8	4
68	The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction. <i>European Review for Medical and Pharmacological Sciences</i> , 2016, 20, 4731-4741.	0.7	43
69	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. <i>Annals of Hepatology</i> , 2015, 14, 325-332.	1.5	3
70	<i>Helicobacter pylori</i> infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. <i>United European Gastroenterology Journal</i> , 2015, 3, 17-24.	3.8	72
71	ENOS dysfunction in Steatosis and Steatohepatitis. <i>Digestive and Liver Disease</i> , 2015, 47, e55.	0.9	0
72	Steatosis in patients with HCV chronic liver disease: Baseline results from patients enrolled in the PITER cohort study. <i>Digestive and Liver Disease</i> , 2015, 47, e224-e225.	0.9	0

#	ARTICLE	IF	CITATIONS
73	Lung ultrasound for diagnosis of pneumonia in emergency department. <i>Internal and Emergency Medicine</i> , 2015, 10, 851-854.	2.0	48
74	Non Alcoholic Fatty Liver: Epidemiology and Natural History. <i>Reviews on Recent Clinical Trials</i> , 2015, 9, 126-133.	0.8	215
75	Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. <i>Hepatitis Monthly</i> , 2015, 15, e18640.	0.2	7
76	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. <i>Annals of Hepatology</i> , 2015, 14, 325-32.	1.5	0
77	Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy. <i>Italian Journal of Medicine</i> , 2014, , .	0.3	0
78	Etiology of newly-diagnosed cases of chronic liver disease in Southern Italy: results of a prospective multicentric study. <i>Italian Journal of Medicine</i> , 2014, 8, 176.	0.3	2
79	The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. <i>BMC Research Notes</i> , 2014, 7, 59.	1.4	6
80	No differences of response to telaprevir based therapy in cirrhotic and non cirrhotic patients with RVR: Real life data from South Italy. <i>Digestive and Liver Disease</i> , 2014, 46, e134-e135.	0.9	0
81	Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. <i>BMC Gastroenterology</i> , 2014, 14, 31.	2.0	24
82	Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 16841.	3.3	36
83	Diaphragmatic motility assessment in COPD exacerbation, early detection of Non-Invasive Mechanical Ventilation failure: a pilot study. <i>The Ultrasound Journal</i> , 2014, 6, .	2.0	7
84	Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. <i>World Journal of Gastroenterology</i> , 2014, 20, 15233.	3.3	57
85	890 HIGH PREVALENCE OF SVR TO STANDARD OF CARE THERAPY IN INJECTION DRUG USERS (IDUS): AN ITALIAN MONOCENTRIC STUDY. <i>Journal of Hepatology</i> , 2013, 58, S366.	3.7	0
86	Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. <i>Medical Hypotheses</i> , 2013, 81, 913-915.	1.5	18
87	OC-14 Prevalence of occult HBV infection reactivation in a large cohort of Non-Hodgkin Lymphoma (NHL) patients: a retrospective study. <i>Digestive and Liver Disease</i> , 2012, 44, S5-S6.	0.9	0
88	F-47 Clinical and genetic factors of response to antiviral treatment of chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2012, 44, S46-S47.	0.9	0
89	Coeliac disease and C virus-related chronic hepatitis: a non association. <i>BMC Research Notes</i> , 2012, 5, 533.	1.4	10
90	Antiviral therapy: why does it fail in HCV-related chronic hepatitis?. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 535-543.	4.4	17

#	ARTICLE	IF	CITATIONS
91	P.1.6: CONTRAST ENHANCED ULTRASOUND (CEUS) IN THE CHARACTERIZATION OF FOCAL LESIONS IN BRIGHT LIVER OF ONCOLOGY PATIENTS. <i>Digestive and Liver Disease</i> , 2011, 43, S149-S150.	0.9	0
92	HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. <i>Acta Diabetologica</i> , 2011, 48, 337-343.	2.5	22
93	Inferior vena cava collapsibility to guide fluid removal in slow continuous ultrafiltration: a pilot study. <i>Intensive Care Medicine</i> , 2010, 36, 692-696.	8.2	62
94	Indirect markers of non-alcoholic fatty liver disease: Another piece of the puzzle?. <i>Digestive and Liver Disease</i> , 2010, 42, 846-847.	0.9	1
95	F.N.44 HEPATIC RETINOL BINDING PROTEIN 4 (RBP-4) LEVELS ARE SIGNIFICANTLY RELATED TO THE STEATOHEPATITIS GRADE (COMPROMISSION) BUT NOT WITH HCV INFECTION. <i>Digestive and Liver Disease</i> , 2010, 42, S49.	0.9	0
96	F.N.45 NAFLD PREVALENCE IN NEW DIAGNOSED CASES OF LIVER DISEASE IN SOUTHERN ITALY: RESULTS OF A PROSPECTIVE MULTICENTRIC STUDY. <i>Digestive and Liver Disease</i> , 2010, 42, S49.	0.9	0
97	Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563]. <i>Journal of Hepatology</i> , 2009, 50, 438.	3.7	0
98	Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: Differences and similarities. <i>World Journal of Gastroenterology</i> , 2009, 15, 462.	3.3	24
99	The Impact of Diet on Liver Fibrosis and on Response to Interferon Therapy in Patients With HCV-Related Chronic Hepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, 3159-3166.	0.4	17
100	Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. <i>Journal of Hepatology</i> , 2008, 49, 557-563.	3.7	68
101	Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients. <i>Gut</i> , 2007, 56, 1470-1471.	12.1	12
102	[629] THE INFLUENCE OF OBESITY AND DIABETES ON CLINICAL AND THERAPEUTICAL OUTCOME IN HCV RELATED CHRONIC HEPATITIS: AN ITALIAN NATIONWIDE SURVEY STUDY (PROBE GROUP). <i>Journal of Hepatology</i> , 2007, 46, S238.	3.7	0
103	Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease. <i>Journal of Viral Hepatitis</i> , 2007, 14, 070501060544001-???	2.0	8
104	507 The role of HBV occult infection in patients with non-hodgkin lymphoma: Prevalence and treatment options with nucleotide analogues. <i>Journal of Hepatology</i> , 2006, 44, S189.	3.7	0
105	600 Association of metabolic syndrome, diabetes, iron metabolism and steatosis in HCV and HBV related chronic hepatitis: Differences and similarities. <i>Journal of Hepatology</i> , 2006, 44, S222-S223.	3.7	0
106	Interference of diet on liver histology and on the response to interferon therapy in patients with HCV-related chronic liver disease. <i>Digestive and Liver Disease</i> , 2006, 38, S31.	0.9	0
107	The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. <i>Digestive and Liver Disease</i> , 2006, 38, 485-489.	0.9	276
108	Interleukin-10 ^{rs1082} GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2006, 45, 779-785.	3.7	54

#	ARTICLE	IF	CITATIONS
109	Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. <i>Journal of Viral Hepatitis</i> , 2006, 13, 290-296.	2.0	43